CONSOLIDATED STATEMENTS OF (LOSS) INCOME - USD ($) shares in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Revenues
Product sales	$ 9,536,000,000	$ 10,292,000,000	$ 8,046,000,000
Other revenues	138,000,000	155,000,000	160,000,000
Total revenues	9,674,000,000	10,447,000,000	8,206,000,000
Expenses
Cost of goods sold (exclusive of amortization and impairments of finite-lived intangible assets shown separately below)	2,572,000,000	2,532,000,000	2,178,000,000
Cost of other revenues	39,000,000	53,000,000	58,000,000
Selling, general and administrative	2,810,000,000	2,700,000,000	2,026,000,000
Research and development	421,000,000	334,000,000	246,000,000
Amortization of intangible assets	2,673,000,000	2,257,000,000	1,427,000,000
Goodwill impairments	1,077,000,000	0	0
Asset impairments	422,000,000	304,000,000	145,000,000
Restructuring and integration costs	132,000,000	362,000,000	382,000,000
Acquired in-process research and development costs	34,000,000	106,000,000	20,000,000
Acquisition-related contingent consideration	(13,000,000)	(23,000,000)	(14,000,000)
Other expense (income) (Note 16)	73,000,000	295,000,000	(263,000,000)
Total expenses	10,240,000,000	8,920,000,000	6,205,000,000
Operating (loss) income	(566,000,000)	1,527,000,000	2,001,000,000
Interest income	8,000,000	4,000,000	5,000,000
Interest expense	(1,836,000,000)	(1,563,000,000)	(971,000,000)
Loss on extinguishment of debt	0	(20,000,000)	(130,000,000)
Foreign exchange loss and other	(41,000,000)	(103,000,000)	(144,000,000)
Gain on investments, net (Note 23)	0	0	293,000,000
(Loss) income before (recovery of) provision for income taxes	(2,435,000,000)	(155,000,000)	1,054,000,000
(Recovery of) provision for income taxes	(27,000,000)	133,000,000	174,000,000
Net (loss) income	(2,408,000,000)	(288,000,000)	880,000,000
Less: Net income (loss) attributable to noncontrolling interest	1,000,000	4,000,000	(1,000,000)
Net (loss) income attributable to Valeant Pharmaceuticals International, Inc.	$ (2,409,000,000)	$ (292,000,000)	$ 881,000,000
(Loss) earnings per share attributable to Valeant Pharmaceuticals International, Inc.
Basic (in dollars per share)	$ (6.94)	$ (0.85)	$ 2.63
Diluted (in dollars per share)	$ (6.94)	$ (0.85)	$ 2.58
Weighted-average common shares
Basic (in shares)	347.3	342.7	335.4
Diluted (in shares)	347.3	342.7	341.5